NIH delivers gene therapy to the inside of mitochondria; Bio-Path completes toxicity study of its infusion-based cancer candidate;

> NIH researchers have deployed an adeno-associated virus that enters mitochondria to deliver DNA to improve the vision of mice. More

> Bio-Path Holdings successfully completed a Phase Ib toxicity study of its lead compound, Liposomal Grb-2, for patients with advanced acute myeloid leukemia. It uses the company's liposomal delivery technology that enables intravenous infusions. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.